This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Plotkin, S. R. Articles by Batchelor, T. T. Search for Related Content PubMed PubMed Citation Articles by Plotkin, S. R. Articles by Batchelor, T. T. Related Collections Clinical Research Clinical Research: Clinical Trials

Treatment of Relapsed Central Nervous System Lymphoma with High-Dose Methotrexate

Departments of ¹ Neurology and of ² Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; ³ Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts; ⁴ The Johns Hopkins Oncology Center, Baltimore, Maryland; ⁵ Wake Forest University School of Medicine, Winston-Salem, North Carolina; and ⁶ University of Alabama at Birmingham School of Medicine, Birmingham, Alabama

Purpose: Over the past decade, high-dose methotrexate has emerged as the single most effective agent in the initial treatment of primary nervous system lymphoma. However, the majority of patients who respond initially to treatment relapse. The optimal management of these patients has not been determined. We performed a multicenter, retrospective study of high-dose methotrexate in patients with relapsed central nervous system lymphoma.

Experimental Design: Patients with relapsed disease were eligible if they achieved a complete response to initial treatment with methotrexate-based chemotherapy or received methotrexate after gross total resection or interstitial radiation. All of the patients were retreated with a regimen containing high-dose methotrexate (3 g/m²).

Results: Twenty-two patients with a median age of 58 years were included in the study. Overall response rates were 91% to first salvage (20 of 22 patients) and 100% to second salvage (4 of 4 patients). Median survival was 61.9 months after first relapse (95% confidence interval, 42.1–) and 91.9 months overall (95% confidence interval, 47.2–). Toxicity was primarily hematologic with 10 episodes of grade 3 or 4 toxicity during 566 cycles of chemotherapy.

Conclusions: These results indicate that high-dose methotrexate remains effective for relapsed central nervous system lymphoma in patients who initially respond to methotrexate and raise the possibility of deferring more toxic salvage regimens in this select group of patients.

This article has been cited by other articles:

				C. Soussain, K. Hoang-Xuan, L. Taillandier, E. Fourme, S. Choquet, F. Witz, O. Casasnovas, B. Dupriez, B. Souleau, A.-L. Taksin, et al. Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire J. Clin. Oncol., May 20, 2008; 26(15): 2512 - 2518. [Abstract] [Full Text] [PDF]

				T. Batchelor and J. S. Loeffler Primary CNS Lymphoma J. Clin. Oncol., March 10, 2006; 24(8): 1281 - 1288. [Abstract] [Full Text] [PDF]

				L. M. DeAngelis and F. M. Iwamoto An Update on Therapy of Primary Central Nervous System Lymphoma Hematology, January 1, 2006; 2006(1): 311 - 316. [Abstract] [Full Text] [PDF]

				T. T. Batchelor, B. R. Buchbinder, and N. L. Harris Case 1-2005 - A 35-Year-Old Woman with Difficulty Walking, Headache, and Nausea N. Engl. J. Med., January 13, 2005; 352(2): 185 - 194. [Full Text] [PDF]

				Minerva BMJ, October 23, 2004; 329(7472): 986 - 986. [Full Text] [PDF]